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The National Institute for Health and Care Excellence (NICE) in England and Wales 
is currently piloting a process whereby decision problem meetings are held sev-
eral months before starting a technology appraisal, rather than approximately 10 
weeks after formal invitation for the manufacturer to submit evidence, per current 
protocol. In general, the purpose and outcomes of the meeting, involving the NICE 
team and representatives from the evidence research group (ERG), do not change 
other than happening earlier. However, the meeting does allow manufacturers and 
sponsors to signal potential regulatory developments during the appraisal, ahead 
of the submission, to indicate potential inclusion and handling of patient access 
scheme proposals. For the meeting, an outline is required to demonstrate how the 
manufacturer/sponsor intends to approach the decision problem. This outline is 
to include, but is not limited to: evidence sources to be used; evidence likely to 
become available during the appraisal and how this might be managed; the planned 
approach to disease and economic modelling; potential challenges in interpreting 
the evidence; proposed approach to handling of uncertainty. If adopted, there are 
several implications of this new process for manufacturers/sponsors: market access 
strategy will need to be considered earlier than currently, with implications for data 
availability and analyses, value story development, positioning and indications, 
etc; cost-effectiveness models and their base cases will need earlier definition and 
completion; intentions regarding patient access schemes must be made before sub-
mission; ERGs may be reviewing limited published evidence in fast-moving therapy 
areas;, manufacturer market access groups will require more information from 
clinical, regulatory, medical affairs, modellers, epidemiologists much sooner that 
they currently do. Therefore, this seemingly simple change of meeting date rela-
tive to time of submission has important implications for manufacturers beyond 
their market access teams that require careful consideration in terms of planning 
and communication.
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Irish legislation recognises the need to consider the cost-effectiveness of health 
services, both for new interventions and their opportunity cost. Ireland did not 
have an explicit cost-effectiveness threshold until a 2012 agreement between the 
pharmaceutical industry and government established a € 45,000/QALY threshold. 
It was agreed as part of a deal that provided cost savings on existing medications 
and only applies to pharmaceuticals: there is no official threshold for non-drug 
interventions. Drugs with cost-effectiveness ratios within the threshold are guar-
anteed reimbursement, whereas those exceeding the threshold may be approved 
following further negotiation. A number of drugs far exceeding the threshold have 
been reimbursed in Ireland in recent years. There are four reasons for concern 
regarding Ireland’s threshold. Firstly, as a price floor not a ceiling it offers only a 
weak constraint on the introduction of cost-ineffective interventions, which leaves 
little scope for positive net health benefit. Secondly, that the threshold only applies 
to drugs creates potential for inconsistencies whereby relatively cost-effective 
non-drug interventions may not necessarily be approved, leading to sub-opti-
mal resource allocation. Thirdly, the current threshold has no apparent empiri-
cal basis. Finally, recent efforts to determine the appropriate cost-effectiveness 
threshold in the UK have estimated a threshold of approximately £13,000/QALY. 
Assuming Ireland’s threshold should be broadly comparable, the current Irish 
threshold is most probably too high. Consequently, reimbursing new interven-
tions at and above the € 45,000/QALY threshold is likely to result in net harm, as 
new drugs produce less health than the interventions they displace. The failure 
of Ireland’s threshold to be empirically determined by the cost-effectiveness of 
services foregone means the requirements of current legislation are not being 
met and reimbursement decisions cannot be considered fully evidenced-based. 
It is likely the current threshold is excessive and will lead to systematic damage 
of the health system.
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BAckground: Observational studies have been one of the hallmarks for the devel-
opment of public health and health economics fields. It includes epidemiologic stud-
ies, evaluation of patterns of care, use of resources, cost of illness, analysis of safety 
and effectiveness of interventions from real world. However, there are different pat-
terns of requirements for ethics reviews concerning observational studies, including 
vastly available models of ethics systems among different countries. Therefore, 
the objective of this study is to evaluate the ethics system, regulations and guide-
lines concerning observational studies in the selected countries. Methodology: 
Guidelines and regulations from Brazil, Argentina, Japan, New Zealand, Australia, 
USA and UK were reviewed to evaluate the ethics system and available guiding 
principle for observational studies. Additionally, a literature review was performed 
in the database Medline and SciELO mesh using the terms “ethics”, “observational 
study” and “multicenter study” among other similar terms. results: In Brazil, 
same ethics regulation is applied for both interventional and observational projects, 
plus there is unsatisfactory ethics review timelines and duplicity of ethics review 
when considering multicenter studies. Specific pathways for multicenter studies 
are available only in New Zealand, Australia, USA and UK. For the exception of Brazil, 
other evaluated countries have specific guidelines, recommendations or regulations 
for observational studies. conclusions: Brazil and Argentina still have a lot of 
and governmental authorities, case studies and the latest publications in value-based 
assessment (VBA) was performed to summarise the current perception of RWD, and 
to identify the advantages and challenges of using RWD to support market access and 
reimbursement. Only 10 guidelines were found from 73 European HTA agencies or 
governmental authorities which cited RWD as a source for evidence. NICE acknowl-
edges the difficulties of generalising RCT results to clinical practice, and supports 
the capture and analysis of observational data. In addition, recent developments in 
VBA anticipate a greater scrutiny of attempts to model natural history in economic 
evaluations, which may be addressed by using longitudinal observational data. Case 
studies have shown economic evaluations based on RCT data may lack external 
validity, and may consequently produce inaccurate estimates of economic endpoints. 
There is a consensus that RWD are valuable in providing clinical practice evidence on 
treatment pathways, resource use, long-term natural history and true effectiveness. 
However, there are methodological challenges (such as lack of randomisation) to 
be addressed before RWD are widely accepted as a complement to RCTs to support 
decision-making. RWD are increasingly recognised as a valuable source of evidence 
for market access and reimbursement, and as a complement to clinical trial evidence. 
Nevertheless, there are challenges that need to be addressed to ensure real world data 
provide valid evidence to the decision process.
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Combinations of high-cost branded drugs are becoming a reality. The synergistic 
value of combining two potent drugs is expected to considerably bolster the benefit 
to the patient in terms of efficacy and, in some cases, even safety. However, the syn-
ergistic cost of using branded combinations increases exponentially due to longer 
treatment durations, thus making the total treatment cost unaffordable to European 
health systems. This poster aims to explore the pricing and reimbursement issues 
that health systems will encounter during the evaluation of branded combination 
therapies and potential solutions to make these combinations affordable by the 
health care systems and ensure patient access to innovative drugs. To meet these 
objectives, an in-depth review of published sources was conducted, including a 
thorough analogue assessment. Moreover, targeted interviews with twenty payers 
involved at different levels of pricing and market access decision-making in the 
EU5 were also conducted to support analysis. Research revealed that synergistic 
costs of already expensive monotherapies, further exacerbated by longer duration 
of treatment, exceed payers’ cost thresholds. Therefore, on one hand payers will 
struggle to award a value-based price for the individual drugs as well as for the 
combination and will look to discount and/or restrict access. On the other hand, as 
this approach will not reflect the combination’s synergistic value and could threaten 
the life-cycle indications of each compound, manufacturers may not launch in some 
markets, thus, limiting patient access. Consequently, it is important to find a balance 
in setting a value-based price for individual indications and for the combinations 
to ensure broad patient access. Aligning patient, payer and manufacturer needs is 
paramount to find a win-win-win solution. In the context of brand-on-brand combi-
nations, traditional pricing models are not the solution and alternative approaches 
need to be adopted.
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BAckground: Knowledge of payer evidence requirements is vital to manufac-
turers who are facing increasing development costs for uncertain market access 
outcomes. Failure to engage payers early in asset development could result in delay 
of approval and/or coverage. oBjectives: Build the case for early payer engage-
ment as a means of reconciling the needs of payers and manufacturers Methods: 
A literature search was performed and primary research with key opinion leaders 
in the US and EU was conducted to characterize 5 early engagement strategies 
(informal consultation, formal consultation, outcomes-based risk sharing, financial-
based risk sharing, and formal partnerships). 7 major markets (Canada, France, 
Italy, Germany, Spain, UK, and US) were also assessed for their historic use of early 
engagement models. results: Payers want more manufacturer involvement in evi-
dence development, including input into clinical trial design and RWE development 
in phases II and III through formal and informal consultations. Articulation of an 
asset’s value story in the peri-launch phase and negotiations with regional and local 
payers through direct consultations allows manufacturers to position the asset for 
optimal pricing and reimbursement. When agreement cannot be reached on price 
or reimbursement terms, risk-sharing agreements allow broader access in exchange 
for the manufacturer bearing incrementally greater financial risk. Manufacturers 
have also built partnerships to uncover the real-world value of therapies and gain 
insight into usage and adherence patterns. Each market has its own challenges 
for promoting collaboration, requiring manufacturers to tailor their approach to 
the various national and local payers conclusion: Early planning is imperative 
in value-focused health care. When early payer engagement succeeds, it provides 
manufacturers time to design informed strategies to meet payer valuation needs. 
Evidence development that is closely aligned with payer requirements results in 
therapies that are more cost effective and gain quicker market access, benefitting 
manufacturers, payers, and patients alike.
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value Based PrICIng
Hulshof J.A.M.
Simon-Kucher & Partners, Bonn, Germany
It is a common perception that the cost of pharmaceutical care, driven by the price 
of medicines, is a major contributor to increasing public health care expenditure, 
the culprit of unsustainability of health care systems. This presentation shows how 
the net effect of value-based pricing of new, innovative treatments and competi-
tive pricing of older, often generic, products defeats that perception. The growth 
of pharmaceutical expenditure is, in fact, leveling off in most European countries, 
a trend that started even before the economic crisis of 2008. Value based pricing 
is an approach by which the pricing strategy is determined by therapeutic value, 
economic value and cost-effectiveness. Value based pricing requires a substan-
tial body of sophisticated evidence, generated throughout product development. 
Competitive pricing is an approach by which the pricing strategy of older products 
is defined relative to the price of direct competitors in order to maximize market 
share. Competitive pricing occurs in crowded markets with multiple equal or undif-
ferentiated treatment options. In recent years, competitive pricing has brought the 
price of many widely prescribed drugs significantly down. These two approaches 
to strategic pricing take place against the backdrop of tightening public financing 
rules that aim at ensuring financial sustainability of publicly financed health care 
systems. Consequence thereof is a two-tiered market access decision-making rou-
tine: for high-value/high-priced innovative treatments centralized decision-making 
based on value assessment with evidence, restricting them to a tightly characterized 
severely ill patient sub-population with low volume and/or a sales ceiling; versus 
local decision-making based on lowest (net) price for high-volume multisource 
products or equivalent single-source products, leading to significantly lower (net) 
prices than the originator at time of launch. Sustainable pharmaceutical care with 
openness towards innovation is therefore within reach.
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Economics is a social science that has a focus on allocating limited resources effi-
ciently. In health care is essential to invest properly, assuring access to health tech-
nologies with the best cost-effective profile, ensuring the sustainability of National 
Health Systems. In Portugal, the INFARMED – National Authority of Medicines and 
Health Products I.P., has been making economic evaluations of medicines for 15 
years, and is currently developing the National Health Technology Assessment 
System – SiNATS, of the utmost importance to the National Health System. 
Nowadays the assessment of the technologies (relative effectiveness assessment 
and cost-effectiveness) is focused on medicines, within the reimbursement process 
and the preliminary assessment to its acquisition by the National Health System’s 
Hospitals. Consequently, it is always done before the reimbursement decision, as 
a supporting tool to the decision itself. The purpose of this model is to guarantee 
a global system, and at the same time, extending it to new technologies besides 
medicines, e.g. medical devices. In these cases, the cost-effectiveness evaluation will 
be done through the whole life-cycle of that technology, affecting its price and use 
considering its real performance; instead of only its market entry. The INFARMED, 
by developing SiNATS, intends to contribute to minimize expenditures in health and 
the citizens’ life quality, in order to assure the National Health System’s sustain-
ability and efficient usage of public resources in health. Moreover, this system also 
aims to observe the technologies’ effectiveness and its usage, with the purpose of 
reducing wastes as well as to promote and award innovation and equal access to 
health technologies. This research intends to verify the applicability of the univer-
sal key principles of Health Technology Assessment Systems in SiNATS, in order 
to guarantee that the model achieves its proposing objectives. The study will be 
focused on the structure of system.
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Orphan drugs are medicines used to the treat life-threatening or chronic diseases 
affecting very rare diseases. From April 2000 to October 2010, 720 drugs received 
orphan drug designation from the European Medicines Agency (EMA). Hereof, 63 
were granted marketing a marketing authorization. Since then - with an annual 
orphan drug sales volume of more than $6 billion - there has been a steady increase 
in applications for orphan designation with the Committee for Orphan Medicinal 
Products (COMP), averaging ten positive recommendations per month. Although 
central approval of orphan drugs covers 30 European countries, it does not neces-
sarily provide for national availability as each national authority has to agree to 
market access and reimbursement. Further, the hospital sector is known for its 
high diversity in terms of national access mechanisms and degree of centralization, 
exemplified by the Nordic Countries: In Denmark and Norway a highly centralized 
hospital sector prevails with one main hospital procurement agency (AMGROS in 
Denmark and LIS in Norway), while in Sweden and Finland several county councils 
are authorized to make decisions independently from each other. The objective of 
the present study is to identify and evaluate possible short cut routes to market 
access and reimbursement for orphan drug hospital only medicines (OD-HOM) in EU 
and further investigate country specific requirements for identified short cut routes 
to market access and reimbursement for OD HOM in EU as strategic options. A litera-
ture review and further desk research was performed. The following countries are 
included in the analysis: Nordic Countries, Germany, France, The Netherlands and 
Spain. The results of the ongoing OD-HOM research will be displayed as a summary 
challenges to overcome regarding the overall ethics system. Applying same ethics 
regulations or guidelines from interventional studies may not be the most adequate 
choice for observational studies.
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The Austrian health care system incurs costs of 30 billion/year, the bulk of the costs 
(77%) are publicly financed. Health policy and decision planning based on research 
evidence helps to tackle increasing costs. The urgent need for the evaluation of 
new health technologies, services, infrastructure, as well as for the development 
of improved technologies for the analysis, planning and control of health systems 
is met by DEXHELPP. Methods: Today, decision support in health care is usually 
based on evidence from studies of limited size, but not yet on the analysis of 
large volumes of routinely collected health care data. DEXHELPP is dedicated to 
filling the gap by combining academic excellence by research partners with profes-
sional implementation including knowledge of commercial partner institutions. 
By doing so special methods for statistical analysis, simulation and visualisation 
will be implemented as well as new methods for documentation and provid-
ing of k-anonymity for used individual data. For this task, existing cooperation 
schemes provide a firm substantial and conceptual knowledge base. All relevant 
fundamental technological competencies from academic and applied research 
are provided by the consortium, coming from universities, competence centres, 
and R&D SMEs. results: Developed methods will help in (1) analysing the status 
quo, (2) making reliable prognoses, and (3) evaluating the consequences of inter-
ventions. A scientific research server with routine data in order to test developed 
methods will be run. The project covers all relevant areas within this complex pro-
cess, from data management via analysis and modelling through to user friendly 
presentation of results and quality assurance. Some of the most important actual 
decision-makers in Austria complete the consortium with application-oriented 
expertise. conclusions: DEXHELPP focusses on the development on high inno-
vative technological methods. Future focus will lay on building up a network 
with more stakeholders to integrate those methods in national and international 
processes.
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The rationale for patient and public involvement (PPI) in the Health Technology 
Assessment (HTA) process has been widely documented. Engagement of patients or 
public in the process facilitates a broadening of scope and delineates a role for the 
patient as an ‘expert witness’ who has unique insight to living with an illness and 
the potential benefits/disadvantages (including side effects) that medical technol-
ogy may offer. Our objective was to explore the concept of practical and meaningful 
public participation in the HTA process and present a research protocol to propose 
a PPI framework applicable to the Irish context. A qualitative systematic literature 
review and concept analysis was used to identify key attributes relating to patient 
and public involvement. It is proposed that this knowledge will be supplemented 
through semi-structured interviews of key informants and a review of a purposive 
sample of HTA agency websites. Researchers, decision makers and policy makers 
will contribute to development and refinement a framework through a process of 
deliberation. Capturing the diverging perceptions of key informants will lead to the 
enhancement of the proposed framework. The role of the publics will be clarified, 
various levels and methods of PPI further defined. This research will explore the 
concept of PPI and suggest a study protocol for the development of a framework for 
PPI in the context of the Irish HTA process.
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Manufacturers and suppliers of potentially life-saving drugs must ensure adequate 
supplies of in-date drug formulations for all markets across Europe. Failure to do 
so risks patient lives, but stock-outs have occurred even when a manufacturer has 
“over-supplied” a market with many times the amount of drug expected to meet 
local demand. These stock-outs have occurred as a result of parallel trade. In these 
cases, as little as a 10% variance on pack cost is enough to trigger parallel trade, 
which can result from price variations at launch across the EU and currency fluc-
tuations following launch. These situations form a useful series of case studies to 
determine supply chain issues leading to stock-outs. Based on this case study analy-
sis, a model is being developed to estimate the degree of exposure to risk of parallel 
trade and its associated potential cost to the manufacturer/supplier, and to patient 
access. The model identifies and quantifies trade flow patterns and key elements. 
Consequently, supply planning is possible based on essential metrics identified in 
the trade flow patterns. An allocation scheme to meet local needs is the key output 
of the model. The allocation scheme is applied to limit stock to the country to be 
in line with demand, plus a smaller variance (depending on local conditions) for 
that market compared to that previously applied. The model is intended for use in 
key EU markets (France, Germany, Italy,  The Netherlands, Spain, Italy, UK) as well 
as countries in Central and Eastern Europe. The model should help to optimise 
supply chain planning and operations, thereby minimising the risk of stock-outs. 
Consequently, all patients requiring specific, potentially life-saving drugs should 
have access to these treatments.
